GNPX

$0.00

(

0.00%

)
Quote details

stock

Genprex Inc

NASDAQ | GNPX

2.90

USD

$0.00

(

0.00%

)

At Close (As of Nov 26, 2025)

$6.76M

Market Cap

0.0974

P/E Ratio

42.5

EPS

$63.00

52 Week High

$2.77

52 Week Low

HEALTHCARE

Sector

GNPX Chart

Recent Chart
Price Action

GNPX Technicals

Tags:

GNPX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$6.7K
Total Revenue $0
Cost Of Revenue $6.7K
Costof Goods And Services Sold $6.7K
Operating Income -$21M
Selling General And Administrative $11B
Research And Development $11M
Operating Expenses $21M
Investment Income Net -
Net Interest Income $64K
Interest Income $64K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $6.7K
Income Before Tax -$21M
Income Tax Expense -$21B
Interest And Debt Expense -
Net Income From Continuing Operations -$21M
Comprehensive Income Net Of Tax -
Ebit -$21M
Ebitda -$21M
Net Income -$21M

Revenue & Profitability

Earnings Performance

GNPX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4.1M
Total Current Assets $2.1M
Cash And Cash Equivalents At Carrying Value $1.6M
Cash And Short Term Investments $1.6M
Inventory -
Current Net Receivables -
Total Non Current Assets $2M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $1.6B
Other Current Assets $476K
Other Non Current Assets -
Total Liabilities $2.5M
Total Current Liabilities $2.5M
Current Accounts Payable $1.1M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $1.4M
Other Non Current Liabilities -
Total Shareholder Equity $1.6M
Treasury Stock -
Retained Earnings -$155M
Common Stock $11K
Common Stock Shares Outstanding $80K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$17M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $6.7K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $1.2K
Cashflow From Financing $12M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $277M
Dividend Payout Common Stock $277M
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$21M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$6.7K
Total Revenue $0
Cost Of Revenue $6.7K
Costof Goods And Services Sold $6.7K
Operating Income -$21M
Selling General And Administrative $11B
Research And Development $11M
Operating Expenses $21M
Investment Income Net -
Net Interest Income $64K
Interest Income $64K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $6.7K
Income Before Tax -$21M
Income Tax Expense -$21B
Interest And Debt Expense -
Net Income From Continuing Operations -$21M
Comprehensive Income Net Of Tax -
Ebit -$21M
Ebitda -$21M
Net Income -$21M

GNPX News

GNPX Profile

Genprex Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Genprex, Inc. is a clinical-stage gene therapy company headquartered in Austin, Texas, committed to revolutionizing the treatment landscape for cancer and diabetes. By harnessing unique gene therapies, Genprex aims to address significant unmet medical needs and enhance patient outcomes for challenging diseases. The company is advancing its innovative pipeline through comprehensive clinical trials, establishing itself as a leader in the gene therapy sector and paving the way for transformative medical solutions that could impact countless lives.

LPTX
+368.57%
$2.05
NVDA
+1.37%
$180.26
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+117.39%
$1.06
INHD
-16.32%
$0.22
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
AMZE
+10.76%
$0.39
ONDS
-2.36%
$8.24
AMBR
+56.32%
$2.47
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
NIO
-0.72%
$5.46
IPG
-1.95%
$24.57
ASST
+1.80%
$1.13
CLSK
+13.79%
$13.45
AXDX
-61.36%
$0.03
AAL
+3.49%
$13.93
TSLA
+1.71%
$426.58
CIFR
+9.30%
$19.15
SOFI
+0.56%
$28.49
INTC
+2.73%
$36.81
BMNR
+9.78%
$31.74
GPUS
+15.78%
$0.33
GOOGL
-1.07%
$319.95
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-34.15%
$0.12
MARA
-0.53%
$11.11
WULF
+6.45%
$14.84
HOOD
+10.92%
$128.20
RUBI
-8.19%
$0.21
KVUE
+1.11%
$17.22
F
+0.15%
$13.19
AMD
+3.93%
$214.24
SNDK
-2.47%
$215.04
SOND
-23.45%
$0.12
WBD
+4.00%
$23.88
DNN
+3.64%
$2.56
RMBL
+60.50%
$3.21
TLRY
+4.76%
$1.03
BTBT
+2.65%
$2.32
LNW
-3.71%
$86.22
CHR
-4.86%
$0.04
AMZN
-0.22%
$229.16
ADD
-25.47%
$0.05
GRAB
+1.52%
$5.32
BMNU
+18.42%
$7.52
RIG
+6.17%
$4.30
RIVN
+3.98%
$16.18
PW
+18.87%
$0.99
SRM
+53.27%
$10.30
PLTR
+1.35%
$165.77
PFE
-0.03%
$25.71
AAPL
+0.20%
$277.55
HBAN
+0.55%
$16.27
IVP
-20.80%
$0.13
BBD
+3.95%
$3.68
AGNC
+1.53%
$10.56
CETY
-11.20%
$2.06
BTG
+3.23%
$4.47
BAC
+0.97%
$52.99
KALA
+42.62%
$0.91
CCL
-1.12%
$25.43
BULL
+6.43%
$9.26
SNAP
-0.39%
$7.61
GOOG
-1.03%
$320.28
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
RGTI
-1.95%
$25.57
CRWV
+4.20%
$74.29
AVGO
+3.25%
$397.57
WLGS
-5.57%
$0.04
VALE
+2.62%
$12.51
ABEV
0.00%
$2.51
NFLX
+1.66%
$106.14
MTSR
-0.35%
$70.50
PLTD
-1.37%
$7.16
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
ORCL
+4.02%
$204.96
UPWK
-0.55%
$19.58
NTNX
-17.74%
$48.34
MSFT
+1.78%
$485.50
ITUB
+3.23%
$7.66
DVLT
-3.61%
$2.13
PCG
+1.78%
$16.01
NOK
+0.33%
$6.08
DEFT
+20.86%
$1.39
CMG
+1.88%
$34.03
AFMD
-34.94%
$0.18
KOS
-1.83%
$1.07
HBI
-0.45%
$6.59
CAN
+0.75%
$0.92
HPQ
-1.39%
$23.98
BURU
+7.72%
$0.22
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
LPTX
+368.57%
$2.05
NVDA
+1.37%
$180.26
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+117.39%
$1.06
INHD
-16.32%
$0.22
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
AMZE
+10.76%
$0.39
ONDS
-2.36%
$8.24
AMBR
+56.32%
$2.47
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
NIO
-0.72%
$5.46
IPG
-1.95%
$24.57
ASST
+1.80%
$1.13
CLSK
+13.79%
$13.45
AXDX
-61.36%
$0.03
AAL
+3.49%
$13.93
TSLA
+1.71%
$426.58
CIFR
+9.30%
$19.15
SOFI
+0.56%
$28.49
INTC
+2.73%
$36.81
BMNR
+9.78%
$31.74
GPUS
+15.78%
$0.33
GOOGL
-1.07%
$319.95
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-34.15%
$0.12
MARA
-0.53%
$11.11
WULF
+6.45%
$14.84
HOOD
+10.92%
$128.20
RUBI
-8.19%
$0.21
KVUE
+1.11%
$17.22
F
+0.15%
$13.19
AMD
+3.93%
$214.24
SNDK
-2.47%
$215.04
SOND
-23.45%
$0.12
WBD
+4.00%
$23.88
DNN
+3.64%
$2.56
RMBL
+60.50%
$3.21
TLRY
+4.76%
$1.03
BTBT
+2.65%
$2.32
LNW
-3.71%
$86.22
CHR
-4.86%
$0.04
AMZN
-0.22%
$229.16
ADD
-25.47%
$0.05
GRAB
+1.52%
$5.32
BMNU
+18.42%
$7.52
RIG
+6.17%
$4.30
RIVN
+3.98%
$16.18
PW
+18.87%
$0.99
SRM
+53.27%
$10.30
PLTR
+1.35%
$165.77
PFE
-0.03%
$25.71
AAPL
+0.20%
$277.55
HBAN
+0.55%
$16.27
IVP
-20.80%
$0.13
BBD
+3.95%
$3.68
AGNC
+1.53%
$10.56
CETY
-11.20%
$2.06
BTG
+3.23%
$4.47
BAC
+0.97%
$52.99
KALA
+42.62%
$0.91
CCL
-1.12%
$25.43
BULL
+6.43%
$9.26
SNAP
-0.39%
$7.61
GOOG
-1.03%
$320.28
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
RGTI
-1.95%
$25.57
CRWV
+4.20%
$74.29
AVGO
+3.25%
$397.57
WLGS
-5.57%
$0.04
VALE
+2.62%
$12.51
ABEV
0.00%
$2.51
NFLX
+1.66%
$106.14
MTSR
-0.35%
$70.50
PLTD
-1.37%
$7.16
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
ORCL
+4.02%
$204.96
UPWK
-0.55%
$19.58
NTNX
-17.74%
$48.34
MSFT
+1.78%
$485.50
ITUB
+3.23%
$7.66
DVLT
-3.61%
$2.13
PCG
+1.78%
$16.01
NOK
+0.33%
$6.08
DEFT
+20.86%
$1.39
CMG
+1.88%
$34.03
AFMD
-34.94%
$0.18
KOS
-1.83%
$1.07
HBI
-0.45%
$6.59
CAN
+0.75%
$0.92
HPQ
-1.39%
$23.98
BURU
+7.72%
$0.22
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.